The monoclonal antibody trastuzumab (Herceptin), used to treat HER2+ breast cancer (Baselga et al., 1996; Pegram et al., 1998) has been shown to block proteolysis of the HER2 receptor tyrosine kinase as part of its mechanism of action (Molina et al., 2001). Here, ERBB2 is linked to breast carcinoma.